第一单位：
Division of Cardiovascular Medicine and Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA. Electronic address: witteles@stanford.edu.
作者：
Ronald M,Witteles [1]
;
Pablo,Garcia-Pavia [2]
;
Caroline,Morbach [3]
;
Julian D,Gillmore [4]
;
Mark S,Taylor [5]
;
Isabel,Conceição [6]
;
William B,White [7]
;
Cynthia,Kwok [8]
;
Marianne T,Sweetser [8]
;
Katherine L,Boyle [8]
;
David,Adams [9]
作者单位：
Division of Cardiovascular Medicine and Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA. Electronic address: witteles@stanford.edu.
[1]
Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Health Research Institute of the Puerta de Hierro Majadahonda-Segovia, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBER-CV), and Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
[2]
Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, and the Department of Medicine I, University Hospital Würzburg, Würzburg, Germany.
[3]
National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, United Kingdom.
[4]
Department of Clinical Immunology, Liverpool Hospital and South West Sydney Clinical Campus, UNSW Medicine and Health, Sydney, New South Wales, Australia.
[5]
Department of Neurosciences and Mental Health, ULS de Santa Maria, CAML, Faculty of Medicine, Centre of Studies Egas Moniz, University of Lisbon, Lisbon, Portugal.
[6]
Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
[7]
Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
[8]
Department of Neurology, CHU Bicêtre, APHP, INSERM U 1195, University Paris-Saclay, Le Kremlin Bicêtre, France.
[9]
DOI
10.1016/j.jacadv.2025.102066
PMID
40848527
发布时间
2025-09-26
换一批
